Organization: Health Canada
Year: 2025
Month: February
Request Number: A-2022-001491
Request Summary: The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24 for the medicinal ingredient levetiracetam. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for levetiracetam which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24.
Disposition: Disclosed in part
Number of pages: 13